Synapse Microcurrent Ltd. is a leading medical technology based
company specializing in developing and taking to market clinically
proven medical devices to promote advanced tissue healing in a
variety of different applications.
Incorporated in January 2003,
Synapse focussed its efforts in the early years in refining and
securing the rights to patented technology in tissue viability.
Evidence of this came in 2007 when Synapse was awarded ISO 9001:2000*
accreditation for the design and manufacture of its micro-current
devices for medical, veterinary and sports applications.
Commenting
on this achievement John Gildersleeve, Chief Executive of Synapse
Micro-current Ltd said, "Synapse are committed to providing
quality products and services. This is demonstrated by the very
high level of repeat business from our customers, who recognise
the important connection between quality and value. Achieving ISO
9001:2000 certification for our established quality management
system, shows our commitment to providing the high quality and
traceability that our customers expect."
In addition, Synapse gained the ISO 13485:2003 accreditation. David
Chapman-Jones, Director of Medicine and Science said "We are
delighted to achieve ISO 13485:2003 accreditation for our Accel
Heal and Tendonworks units. Synapse aims to comply with the highest
possible standards in the medical devices industry and this quality
management system will ensure a basis for continuously meeting
regulatory requirements now and in the future. This achievement
demonstrates our absolute commitment to the quality of our medical
devices and meeting customers expectations."
*ISO 9001 is the internationally recognised standard for Quality
Management Systems (QMS). ISO 13485 is based on the ISO 9001:2000
process model approach and is a management systems standard specifically
developed for the manufacture of medical devices which is audited
continuously by a certified notified body. Its primary objective
is to facilitate harmonised medical device regulatory requirements.
How does the Synapse micro-current unit differ from other electrical
treatment devices?
In simple terms it is the level or strength of the current used
that differentiates one electrical treatment device from another.
Synapse micro-current operates at similar levels to the body’s
natural electrical systems. In general terms micro-current uses
a very low level of current, operating at cellular level.
This is in contrast to devices using stronger intensity that can
cause muscle contractions as a cause of mechanical effect.
In our body cellular activity and intercellular communication is
regulated (chemically) by electricity and it is the efficiency
of this communication process which is key to a normal physiological
state.The supposition behind Synapse micro-current treatments
is that damaged or disrupted (electro-chemical) pathways (caused
by illness, injury and extreme conditions such as intense exercise)
can be reignited.
Synapse’s patented programs are specifically based on the understanding
that different cell types respond to different treatment parameters.
Cellular activity is sensitive to the treatment and laboratory studies
have demonstrated that cells can be turned 'off' as well as 'on'.
Therefore, if treatment parameters are not accurately delivered there
is the potential to have a detrimental effect. If programs are not
within specific parameters we would question the efficacy.
We would claim our patented programs are quite specific and proven
- the result of nearly 15 years research.
The programs are specific - ie the tendonworks unit is different
to the recovery unit. We know and have proved that cells behave
very differently, they are also very sensitive to the treatment
- we have been able to turn cells 'off' as well as 'on' so if the
treatment parameters are not accurately delivered they can have
a detrimental effect - the same goes for the treatment time.
We accept we are not at the optimum by any means but we know to
be most effective it needs to be within our parameters.
If programs are not within these parameters we would question the
efficacy.
Same goes for the accuracy of the electronics and design - Our
units are accurate to 0.001 % Again less accuracy = less efficacy.
Finally in addition to your acknowledged ease of use our units
have a patented solution to the very 'real world' problem of skin
resistance.
We have carried out a large amount of research into skin resistance.
Healthy skin, different ethnicity, different conditions all give
varying problems to delivering precise current to the area below
the skin surface. Our units indicate when they are not delivering
the programs accurately or effectively. Once notified, remedial
action can be taken such as skin preperation, until the treatment
can be delivered. To illustrate - you could attach a competitors
electrode to a piece of wood/ metal/ car and it would indicate
it was delivering it's alleged program. in short you're completely
in the dark as to what it's doing.
Currently the clinical applications and related products are:-
Wound Care -
facilitating an accelerated rate of healing in all wounds focusing
upon chronic and difficult to heal wounds.
Tendon Healing - the augmentation of the production of type 1 collagen
to promote the regenerative sequence of normal tendon cyclical
tissue turnover.
"Sport" Recovery - Post exercise lactic acid/related
fatigue reduction.
"Sport" Performance - Increases the levels of Adenosine
Tri-Phosphate (ATP). AMP-activated protein kinase (AMPK)
An independent phase III trial (Chronic Wounds) has recently been
completed which succesfully demonstrated Synapse Accel-Heal™ efficacy
with Chronic non healing wounds
The Sports division continues to flourish with the continued use
by many elite athletes & teams. The Recovery & Performance
micro-current units both contain the latest versions of Synapse's
proven sports technology in devices, smaller, lighter and cheaper
than previously available.
John Gildersleeve
Chief Executive
Co-founder of Synapse Microcurrent Ltd.
As an Originator and Co-founder of the Tornado Group (Now World
Television PLC), John was fully involved with all aspects of the
business, including the initial funding and business plan, through
to dealing with all the associated parties involved with a public
floatation, raising £15m. Previously John was Head of the
Music Division of Streets On Line Ltd where he was responsible
for all aspects of Audiostreet.com and Labrador Records, In a short
while, Audiostreet.com was both critically and commercially
acclaimed, being at the time, the most successful music commerce
site in Europe. Streets Online was subsequently acquired
by the Kingfisher Group. John was also formerly a non
executive director of face2face communications , overseeing
the development of communication opportunities that now exist for
corporate companies on the internet. Also overseeing the financial
operations of the company saw the company enjoy record profits
and growth of margin to a healthy 26% (Period end Dec 03)
Dr David Chapman-Jones LLM (Med), FMS, MA (Ed),
MSc, PhD
Director - Medicine & Science
Co-founder of Synapse Microcurrent Ltd.
Trained at the Queens Medical Centre, Nottingham specialising in
Sports and Exercise Medicine, Dr Chapman-Jones focused on the clinical
management of tendon pathology. This resulted in the research and
development of a new treatment focussing upon accelerating tissue
repair using micro-current technology. David has a wealth of clinical
experience specialising in musculo-skeletal ultrasound and diagnostic
soft-tissue imaging , working closely with SonoSite, the leaders
in hand-held ultrasound units. This, in combination with the tendon
research has led him to treat many top sportsmen and elite racehorses
presenting with tendon problems.
In the years 1999/2000 David studied Forensic Medicine, Science
and Law with the Worshipful Society of Apothecaries, Glasgow University
and Guy's Hospital. This led him over the following five years
to obtain an undergraduate Law degree and a Masters of Law in Medical
Law and Medical Ethics. David is a member of the Inner Temple,
Inns of Court and is interested in the subject area concerning
the use of human tissue in medical and scientific research and
the issue of informed consent in all medical procedures. This period
of study has allowed David to gain an a knowledge and experience
that will ensure that the clinical trials Synapse undertake have
the necessary rigor to be scientifically credible and relevant.
Having successfully gained ethical approval previously for micro-current
based research clinical trials this in-house knowledge is valuable
for the company developing its portfolio of products.
David set-up Tendon Works, the commercial division of the tendon
research which has a human and equine speciality. The equine side
treats and manages tendon injuries in racehorses using Synapse's
patented micro-current technology. Tendon Works has treated over
100 good class racehorses to date and is to become a formal Synapse
entity.
John Parkinson
Chairman - Non Exec.
John has over thirty years of experience in commerce, property
and professional sport. John brings to the Board a wealth of both public
and private sector company knowledge along
with an understanding of how businesses are run efficiently and
profitably.
John has previously been
involved with Higgs and Hill
plc (now Hbg Ltd) Swan Hill plc and was formerly Chief
Executive of Newcastle Falcons Rugby Ltd and Managing
Director of Metnor Group PLC.
Martin Zapico
Non - Exec
Martin recently retired from his position as a Managing Director
of Morgan Stanley after 20 years where he was the Global Head of
the Securities Lending, Equity Swaps and Tax Arbitrage businesses.
All of which were voted 'Best of Breed' among their peers. Martin
is also a Director of the Westminster-based award winning Cinnamon
Club restaurant.